UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000041633
Receipt No. R000047524
Scientific Title Predictions for relapse of rheumatoid arthritis after discontinuation of biologics
Date of disclosure of the study information 2020/09/01
Last modified on 2020/09/01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Predictions for relapse of rheumatoid arthritis after discontinuation of biologics
Acronym Predictions for relapse of rheumatoid arthritis after discontinuation of biologics
Scientific Title Predictions for relapse of rheumatoid arthritis after discontinuation of biologics
Scientific Title:Acronym Predictions for relapse of rheumatoid arthritis after discontinuation of biologics
Region
Japan

Condition
Condition Rheumatoid arthritis
Classification by specialty
Clinical immunology
Classification by malignancy Others
Genomic information YES

Objectives
Narrative objectives1 We hypothesized that the molecular status of rheumatoid arthritis patients who are clinically in remission varies from person to person, and that prognosis depends on whether or not they have achieved molecular remission. The aim of this study is to investigate the clinical significance of achieving molecular remission in rheumatoid arthritis patients based on multi-omics analysis that may be a predictor of future relapse.
Basic objectives2 Others
Basic objectives -Others We aim to investigate molecular markers that predict relapse after discontinuation of biologic agents.
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Association between molecular remission status before tocilizumab discontinuation and relapse after discontinuation.
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
16 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria The following individuals who had blood samples stored in the laboratory of Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine with written informed consent: (1) healthy individuals, (2) patients with active rheumatoid arthritis who were untreated at the time of sample collection, (3) patients with rheumatoid arthritis who had achieved clinical remission under tocilizumab at the time of sample collection, and (4) patients with rheumatoid arthritis who had achieved clinical remission under tocilizumab at the time of sample collection and who had discontinued tocilizumab treatment within 12 months of sample collection.
Key exclusion criteria Patients considered unsuitable on medical grounds by study sponsors.
Target sample size 160

Research contact person
Name of lead principal investigator
1st name Katsuya
Middle name
Last name Suzuki
Organization Keio University School of Medicine
Division name Division of Rheumatology, Department of Internal Medicine
Zip code 160-8582
Address 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
TEL 03-5363-3786
Email katsuyas@z5.keio.jp

Public contact
Name of contact person
1st name Nobuhiko
Middle name
Last name Kajio
Organization Keio University School of Medicine
Division name Division of Rheumatology, Department of Internal Medicine
Zip code 160-8582
Address 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
TEL 03-5363-3786
Homepage URL
Email nobuhiko.kajio@keio.jp

Sponsor
Institute Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine.
Institute
Department

Funding Source
Organization Chugai Pharmaceutical Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Certified Review Board of Keio
Address 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
Tel 03-5363-3503
Email med-nintei-jimu@adst.keio.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 09 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2020 Year 01 Month 08 Day
Date of IRB
Anticipated trial start date
2020 Year 09 Month 01 Day
Last follow-up date
2022 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information We conduct comprehensive genetic and proteomic analysis of blood samples from healthy individuals and rheumatoid arthritis patients. and mathematical models will be developed to define molecular remission based on comprehensive molecular and clinical information from healthy individuals and untreated active rheumatoid arthritis patients, and the relationship between molecular remission and imaging and functional assessment in rheumatoid arthritis patients who are in clinical remission will be analyzed. In addition, we will search molecular markers that predict relapse after discontinuation of biologic agents.

Management information
Registered date
2020 Year 09 Month 01 Day
Last modified on
2020 Year 09 Month 01 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047524

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.